Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling.
Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling.
复制标题
DOI：
10.3390/jcm11030483
复制
发表时间：
2022-01-18
影响因子：
3.9
通讯作者：
Pergolizzi B
中科院分区：
文献类型：
--
作者：
Panuzzo C;Jovanovski A;Ali MS;Cilloni D;Pergolizzi B
在过去十年中，关于急性髓性白血病（AML）分子景观的努力创造了获得患者个性化治疗的可能性。事实上，微小残留病（MRD）的准确诊断和精确评估的改进增加了适用于新型靶向治疗的新标志物的数量。这一进展得益于分子技术的发展，从实时定量PCR（Rt-qPCR）开始，经过数字液滴PCR（ddPCR）和下一代测序（NGS），直到新的有吸引力的代谢组学方法。技术进步的目的是更好地描述AML克隆异质性，监测没有疾病特异性突变的患者，并根据MRD评估设计定制的缓解后策略。在这种情况下，代谢组学，这涉及到整体小分子谱，出现了相关的风险分层和靶向治疗的改进。在这篇综述中，我们对血液学实验室中使用的最流行的现代方法进行了详细的概述，指出它们对MRD监测的至关重要性，以提高总生存率，早期发现可能的复发和治疗效果。
The efforts made in the last decade regarding the molecular landscape of acute myeloid leukemia (AML) have created the possibility of obtaining patients’ personalized treatment. Indeed, the improvement of accurate diagnosis and precise assessment of minimal residual disease (MRD) increased the number of new markers suitable for novel and targeted therapies. This progress was obtained thanks to the development of molecular techniques starting with real-time quantitative PCR (Rt-qPCR) passing through digital droplet PCR (ddPCR) and next-generation sequencing (NGS) up to the new attractive metabolomic approach. The objective of this surge in technological advances is a better delineation of AML clonal heterogeneity, monitoring patients without disease-specific mutation and designing customized post-remission strategies based on MRD assessment. In this context, metabolomics, which pertains to overall small molecules profiling, emerged as relevant access for risk stratification and targeted therapies improvement. In this review, we performed a detailed overview of the most popular modern methods used in hematological laboratories, pointing out their vital importance for MRD monitoring in order to improve overall survival, early detection of possible relapses and treatment efficacy.
登录
查看更多内容
影响因子：
6.6
作者：
Della Starza I;Nunes V;Lovisa F;Silvestri D;Cavalli M;Garofalo A;Campeggio M;De Novi LA;Soscia R;Oggioni C;Mussolin L;Biondi A;Guarini A;Valsecchi MG;Conter V;Biffi A;Basso G;Foà R;Cazzaniga G
通讯作者：
Cazzaniga G
影响因子：
7.7
作者：
Floegel A;Stefan N;Yu Z;Mühlenbruch K;Drogan D;Joost HG;Fritsche A;Häring HU;Hrabě de Angelis M;Peters A;Roden M;Prehn C;Wang-Sattler R;Illig T;Schulze MB;Adamski J;Boeing H;Pischon T
通讯作者：
Pischon T
DOI：
10.1016/j.omtm.2021.10.002
发表时间：
2021-12-10
期刊：
Molecular therapy. Methods & clinical development
影响因子：
--
作者：
Badbaran A;Mailer RK;Dahlke C;Woens J;Fathi A;Mellinghoff SC;Renné T;Addo MM;Riecken K;Fehse B
通讯作者：
Fehse B
影响因子：
20.3
作者：
Chendamarai, Ezhilarasi;Balasubramanian, Poonkuzhali;Mathews, Vikram
通讯作者：
Mathews, Vikram
影响因子：
3.7
作者：
Chen Z;Tong Y;Li Y;Gao Q;Wang Q;Fu C;Xia Z
通讯作者：
Xia Z